ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 899.21 thousand shares for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-09-29
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-06-30 was 644.77K shares, a 107.41% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-06-30 was 310.86K shares.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-03-31 was 72.61K shares.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 899.21K shares, a 22.45% decline from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 1.16M shares, a 571.62% increase from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 172.65K shares, a 86.79% decline from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 1.31M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2025-06-30 | 644.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | 644.77K shares derived: sum of 2 quarters · filed 2025-09-29 | 899.21K shares 10-K · filed 2025-09-29 | |
| 2025-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | 254.43K shares 10-Q · filed 2025-05-13 | ||
| 2024-12-31 | 254.43K shares 10-Q · filed 2025-02-14 | |||
| 2024-06-30 | 310.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | 383.48K shares derived: sum of 2 quarters · filed 2024-09-25 | 1.15M shares derived: sum of 3 quarters · filed 2024-09-25 | 1.16M shares 10-K · filed 2024-09-25 |
| 2024-03-31 | 72.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | 838.71K shares derived: sum of 2 quarters · filed 2024-05-15 | 848.71K shares 10-Q · filed 2024-05-15 | 848.71K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 766.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | 776.10K shares 10-Q · filed 2024-02-13 | 776.10K shares derived: sum of 3 quarters · filed 2024-02-13 | 776.10K shares derived: sum of 4 quarters · filed 2024-02-13 |
| 2023-09-30 | 10.00K shares 10-Q · filed 2023-11-14 | 10.00K shares derived: sum of 2 quarters · filed 2023-11-14 | 10.00K shares derived: sum of 3 quarters · filed 2023-11-14 | 174.41K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | 0.00 shares derived: sum of 2 quarters · filed 2023-09-22 | 164.41K shares derived: sum of 3 quarters · filed 2023-09-22 | 172.65K shares 10-K · filed 2023-09-22 |
| 2023-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | 164.41K shares derived: sum of 2 quarters · filed 2023-05-11 | 172.65K shares 10-Q · filed 2023-05-11 | 600.28K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 164.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | 172.65K shares 10-Q · filed 2023-02-10 | 600.28K shares derived: sum of 3 quarters · filed 2023-02-10 | 1.42M shares derived: sum of 4 quarters · filed 2023-02-10 |
| 2022-09-30 | 8.24K shares 10-Q · filed 2022-11-10 | 435.87K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.26M shares derived: sum of 3 quarters · filed 2022-11-10 | |
| 2022-06-30 | 427.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | 1.25M shares derived: sum of 2 quarters · filed 2022-09-09 | 1.31M shares 10-K · filed 2022-09-09 | |
| 2022-03-31 | 822.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | 879.43K shares 10-Q · filed 2022-05-11 | ||
| 2021-12-31 | 56.66K shares 10-Q · filed 2022-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |